Αποτελέσματα Αναζήτησης
Milrinone is a phosphodiesterase inhibitor and inotropic agent used to treat congestive heart failure. It is administered by IV infusion or injection, and has various dosage forms, strengths, and contraindications.
28 Αυγ 2020 · Milrinone is primarily for use in the ICU and perioperative setting. Before initiating this medication, a right heart catheterization may be considered for obtaining hemodynamic measurements to establish the patient's baseline parameters and gauge the patient's response to continuous infusion.
3 Απρ 2024 · Milrinone is a vasodilator that is used as a short-term treatment for life-threatening heart failure. It is given as an infusion into a vein, usually around-the-clock for up to 48 hours, and requires monitoring of heart rate, blood pressure, and kidney function.
Milrinone is a PDE-III inhibitor used for the short-term treatment of acute decompensated heart failure. Learn about its pharmacology, pharmacodynamics, indications, contraindications, and adverse effects from DrugBank, a comprehensive drug knowledge database.
Milrinone is a phosphodiesterase 3 inhibitor that increases heart contractility and decreases pulmonary vascular resistance. It is administered IV only and has some adverse effects such as arrhythmias and hypotension.
26 Δεκ 2019 · Milrinone infusion is one of a few select “non-device” therapies for patients with New York Heart Association (NYHA) class IV, stage D heart failure, which has been associated with an increase in ventricular tachyarrhythmia and atrial fibrillation. Milrinone improves hemodynamics and provides symptomatic relief.
Milrinone is a medication that strengthens the heart muscle and widens blood vessels. It is used to treat heart failure and given by a healthcare provider in a hospital or clinic setting. Learn about its common side effects, interactions, and precautions.
